The daphniphyllum alkaloids have inspired organic chemists to devise novel strategies and to develop tailored methods aimed at synthesizing these complex structures. [1,2] The daphmanidins constitute a recent addition to this structurally diverse class of alkaloids isolated from Daphniphyllaceae. These can be further categorized into two skeletal types, namely type A (hexacyclic) and type C (pentacyclic).[1] The characteristic feature of the A-type alkaloids is an unprecedented hexacyclic structure, which includes a fused dihydropyrrole along with an embedded deca-or octahydrocyclopentazulene (oxide) around a central bicyclo[2.2.2]octane (Scheme 1).Herein, we describe the successful total synthesis of (+)-daphmanidin E, which is also the first synthesis of a type A daphmanidin alkaloid. The key features of the strategy involve rapid access to an enantiomerically pure bicyclo-[2.2.2]octadione and elaboration around its periphery through the implementation of two Claisen rearrangements, a diastereoselective hydroboration, and a cobalt-catalyzed alkylHeck cyclization.Daphmanidin E (1, Scheme 1) was isolated in 2006 from leaves of Daphniphyllum teijsmannii, and was shown to exhibit moderate vasorelaxant activity on rat aorta.[3] The complex architecture with three quaternary stereogenic centers and a central bicyclo[2.2.2]octane core constitutes a challenging target. We became attracted by the possibility of starting from the readily available building block 3, which features two quaternary stereogenic centers and the bicyclo-[2.2.2]octane skeleton with suitably functionalized bridgehead positions (Scheme 2). The C(1) ketone (daphmanidin numbering) provides a handle for the introduction of the quaternary center at C(8) through alkylation reactions or Claisen rearrangements, and one of the bridgehead carboxylate groups would provide entry to the fused dihydropyrrole. Key to the overall plan is a late-stage cyclization through an alkyl-Heck coupling to access the embedded seven-membered ring of the octahydroazulene (see 2, Scheme 2).The synthesis commenced with the C 2 -symmetric, enantiomerically enriched bicyclo[2.2.2]octadione (À)-3 (e.r. ! 95:5; Scheme 3). This compound was obtained by resolution Scheme 2. Retrosynthetic analysis of daphmanidin E (PG = protection group). Scheme 1. Type A daphmanidin alkaloids.Scheme 3. Reagents and conditions: a) 1,3-propanediol, pTsOH (10 mol %), PhH, reflux; then acetone, pTsOH (10 mol %), 50 8C, 88 %; b) KHMDS, 2-(NTf 2 )-pyridine, THF, À40 8C, 87 %; c) C 3 H 5 OSitBuPh 2 , 9-BBN, [Pd 2 (dba) 3 ]/CHCl 3 (2 mol %), AsPh 3 (16 mol %), K 3 PO 4 , DMF/ THF/H 2 O, 45 8C, 89 %; d) BH 3 ·SMe 2 , THF, RT, then NaBO 3 ·4H 2 O; DIBAL, THF, À25 8C, 72 %; e) pTsOH (5 mol %), acetone, 50 8C; BzCl, pyridine, DMAP (cat.), CH 2 Cl 2 , RT, 95 % over 2 steps. pTsOH = ptoluenesulfonic acid, KHMDS = potassium hexamethyl disilazide, 9-BBN = 9-borabicyclo[3.3.1]nonane, dba = dibenzylideneacetone, Bz = benzoyl, DIBAL = iBu 2 AlH, DMAP = 4-dimethylaminopyridine; Tf = trifluoromethylsulfonyl, TBDPS = te...